PARTHENON THERAPEUTICS is discovering novel anti-cancer therapies to break down the barriers of Immune Exclusion that many cancers use to resist attack by the immune system.

Our diverse pipeline of orthogonal programs is aimed reprograming the tumor microenvironment (TME) by targeting the interplay between cancer cells, stromal cells, and immune cells that leads to the formation of both physical and functional barriers that promote Immune Exclusion.

Our lead program, PRTH-101, targets Discoidin Domain Receptor 1 (DDR1) to "punch holes" in the physical barrier of extracellular matrix (ECM) shielding the tumor from immune cell attack. PRTH-101 has entered Phase 1 clinical trials in 1H 2023 and is followed by multiple preclinical discovery projects comprising a sustainable portfolio of first-in-class therapeutics that will begin clinical trials soon after.

We use proprietary AI technology to digitally deconstruct the TME and gain unique insights to enable our Precision Oncology approach for biomarker-driven patient selection strategies.

Parthenon is led by an experienced leadership team with extensive drug development experience in both large pharma and startup biotech environments and is back by a world-class syndicate of investors.

Visit to learn more and come join our team!

We are seeking a self-motivated individual who desires to have a direct impact on the science within our early stage, fast-paced, and dynamic biotech. The candidate will have well-documented scientific expertise in molecular and cellular tumor biology and an abiding interest in drug discovery. This scientist will lead the preclinical in vivo pharmacology efforts across Parthenon's drug discovery pipeline, develop and implement project-specific scientific strategies, investigate efficacy and PK/PD relationships of lead compounds, perform detailed mechanism of action studies internally and with external partners, and ensure completion of activities according to project timelines. This role is highly collaborative, closely works with the translational science team, supports regulatory and IP functions, and has the opportunity to be part of the decision making within the discovery and clinical teams.

Role & Responsibilities:
  • Develop preclinical in vivo pharmacology strategies across Parthenon's oncology drug candidate pipeline and target identification platform
  • Direct and oversee efforts in our internal vivarium space and at CROs and execute strategies to enable project decision making following aggressive timelines
  • Design in vivo studies in syngeneic mouse tumor models to determine antitumor efficacy, pharmacodynamic effects, and pharmacokinetics of drug candidates
  • Apply cutting-edge methods to uncover novel insights into target biology at the cancer cell/stromal cell interface and characterize mechanisms of tumor immune exclusion
  • Closely collaborate with Translational Science group to support biomarker efforts
  • Analyze, interpret, and document study results; contribute to regulatory and IP filings as needed
  • When appropriate, publish high-quality research relevant to the mission of Parthenon

    • PhD and a minimum of 7-9 years of post-graduate experience in preclinical pharmacology, of which at least 3 years in the biopharmaceutical industry, preferably as project lead in oncology
    • Excellent knowledge of human and mouse tumor models in oncology and immune-oncology, and methods to characterize antitumor responses, with emphasis on immune cell characterization, signaling, and stromal biology
    • Expertise in designing and executing pharmacology studies to determine drug antitumor effects and identify pharmacologically active doses in PK/PD studies
    • Experience in downstream analytical methods, including TIL profiling, IHC/IF, RNAseq, and analysis of drug PK and serum biomarkers by ELISA or MSD
    • Direct experience interacting with and/or managing CROs is required
    • Outstanding collaborative and project leadership skills, with the ability to rapidly adapt research plans to deliver data in support of internal needs and project timelines
    • Independent, self-motivated, and innovative with the ability to excel in a goal-oriented, nimble, and fast-moving team environment.
    • Effective communicator of data and results to biologists, clinicians, and business partners
    Contact to apply.

    © 2022 Parthenon Therapeutics Inc. All rights reserved.
    40 Guest St.
    Boston, MA 02135